We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Variant of Phosphorylated Tau Helps Fine Tune Early Diagnosis of Alzheimer’s Disease

By LabMedica International staff writers
Posted on 10 Nov 2022
Print article
Image: In Alzheimer`s disease, changes in tau protein lead to the disintegration of microtubules in brain cells  (Photo courtesy of Wikimedia Commons)
Image: In Alzheimer`s disease, changes in tau protein lead to the disintegration of microtubules in brain cells (Photo courtesy of Wikimedia Commons)

A team of neurodegenerative disease researchers has identified an additional phosphorylated tau protein variant that augments the toolbox of biomarkers for early diagnosis of Alzheimer’s disease.

The tau proteins are a group of six highly soluble protein isoforms produced by alternative splicing from the MAPT (microtubule-associated protein tau) gene. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). They are less common elsewhere but are also expressed at very low levels in CNS astrocytes and oligodendrocytes. Pathologies and dementias of the nervous system such as Alzheimer's disease (AD) and Parkinson's disease are associated with tau proteins that have morphed into hyperphosphorylated insoluble aggregates called neurofibrillary tangles. Recent studies have shown that a biomarker in the blood, phosphorylated tau (P-tau217) can detect Alzheimer's disease as early as 20 years before memory problems become apparent and, most importantly, distinguish Alzheimer's disease from other forms of dementia with about 95% accuracy.

Investigators at North Carolina Central University (Durham, NC, USA) used several tau antibodies and a comprehensive set of site-specific phospho-tau (p-tau) antibodies to analyze samples of post-mortem brain tissue from AD patients and non-AD subjects.

Results of these screening tests revealed that site-specific p-tau antibodies could not only differentiate AD from non-AD brains, but also discriminate AD from other tauopathies. Differential detection of tau aggregates identified several novel p-tau sites as potential new biomarkers. In particular, they showed that p-tau198 was a novel promising AD biomarker with sensitivity and specificity comparable with the existing biomarkers p-tau181 and p-tau217. The results demonstrated that p-tau198 detection could differentiate AD from non-AD controls, and also diagnose AD from related tauopathies.

The investigators concluded that their work provided a new avenue for developing diagnosis and differentiation tools for AD and related tauopathies. Furthermore, they suggested that p-tau198 and p-tau217 could help clinicians intervene early, as new treatments become available, before significant neurological damage occurs.

The study was published in the November 9, 2022, online edition of the journal ACS Chemical Neuroscience.

Related Links:
North Carolina Central University

 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.